{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:03:34Z","timestamp":1793257414359,"version":"4.5.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alice\u2019s Arc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In tumours, hypoxia\u2014a condition in which the demand for oxygen is higher than its availability\u2014is well known to be associated with reduced sensitivity to radiotherapy and chemotherapy, and with immunosuppression. The consequences of hypoxia on tumour biology and patient outcomes have therefore led to the investigation of strategies that can alleviate hypoxia in cancer cells, with the aim of sensitising cells to treatments. An alternative therapeutic approach involves the design of prodrugs that are activated by hypoxic cells. Increasing evidence indicates that hypoxia is not just clinically significant in adult cancers but also in paediatric cancers. We evaluate relevant methods to assess the levels and extent of hypoxia in childhood cancers, including novel imaging strategies such as oxygen-enhanced magnetic resonance imaging (MRI). Preclinical and clinical evidence largely supports the use of hypoxia-targeting drugs in children, and we describe the critical need to identify robust predictive biomarkers for the use of such drugs in future paediatric clinical trials. Ultimately, a more personalised approach to treatment that includes targeting hypoxic tumour cells might improve outcomes in subgroups of paediatric cancer patients.<\/jats:p>","DOI":"10.1038\/s41416-020-01107-w","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T22:02:57Z","timestamp":1603749777000},"page":"539-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Hypoxia and its therapeutic possibilities in paediatric cancers"],"prefix":"10.1038","volume":"124","author":[{"given":"Carolina","family":"Bernauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. K. Stella","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise Y.","family":"Lepicard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4101-7274","authenticated-orcid":false,"given":"Simon P.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-8678","authenticated-orcid":false,"given":"Janet M.","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"1107_CR1","first-page":"6449","volume":"49","author":"P Vaupel","year":"1989","unstructured":"Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449\u20136465 (1989).","journal-title":"Cancer Res."},{"key":"1107_CR2","doi-asserted-by":"crossref","unstructured":"Dhani, N., Fyles, A., Hedley, D. & Milosevic, M. The clinical significance of hypoxia in human cancers. Semin. Nucl. Med. 45, 110\u2013121 (2015).","DOI":"10.1053\/j.semnuclmed.2014.11.002"},{"key":"1107_CR3","first-page":"673","volume":"38","author":"JA Belli","year":"1967","unstructured":"Belli, J. A., Dicus, G. J. & Bonte, F. J. Radiation response of mammalian tumor cells. I. Repair of sublethal damage in vivo. J. Natl Cancer Inst. 38, 673\u2013682 (1967).","journal-title":"J. Natl Cancer Inst."},{"key":"1107_CR4","doi-asserted-by":"crossref","unstructured":"Minassian, L. M., Cotechini, T., Huitema, E. & Graham, C. H. In Hypoxia and Cancer Metastasis (ed. Gilkes, D. M.) 123\u2013139 (Springer, Cham, 2019).","DOI":"10.1007\/978-3-030-12734-3_9"},{"key":"1107_CR5","first-page":"3387","volume":"62","author":"KM Comerford","year":"2002","unstructured":"Comerford, K. M., Wallace, T. J., Karhausen, J., Louis, N. A., Montalto, M. C. & Colgan, S. P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62, 3387\u20133394 (2002).","journal-title":"Cancer Res."},{"key":"1107_CR6","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/MCB.00166-09","volume":"29","author":"G Bellot","year":"2009","unstructured":"Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouyss\u00e9gur, J. et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 29, 2570\u20132581 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"1107_CR7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.13-S3-21","volume":"13","author":"P Vaupel","year":"2008","unstructured":"Vaupel, P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13, 21\u201326 (2008).","journal-title":"Oncologist"},{"key":"1107_CR8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrc2540","volume":"8","author":"JA Bertout","year":"2008","unstructured":"Bertout, J. A., Patel, S. A. & Simona, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967\u2013975 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1107_CR9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ctrv.2007.11.005","volume":"34","author":"JK Adamski","year":"2008","unstructured":"Adamski, J. K., Estlin, E. J. & Makin, G. W. J. The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer. Cancer Treat. Rev. 34, 231\u2013246 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"1107_CR10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"1107_CR11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ctro.2019.01.005","volume":"15","author":"L Spiegelberg","year":"2019","unstructured":"Spiegelberg, L., Houben, R., Niemans, R., De Ruysscher, D., Yaromina, A., Theys, J. et al. Hypoxia-activated prodrugs and (lack of) clinical progress: the need for hypoxia-based biomarker patient selection in phase III clinical trials. Clin. Transl. Radiat. Oncol. 15, 62\u201369 (2019).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"1107_CR12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(17)30401-1","volume":"18","author":"LH Lindner","year":"2017","unstructured":"Lindner, L. H. Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation. Lancet Oncol. 18, 991\u2013993 (2017).","journal-title":"Lancet Oncol."},{"key":"1107_CR13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1089\/ars.2007.1628","volume":"9","author":"P Vaupel","year":"2007","unstructured":"Vaupel, P., H\u00f6ckel, M. & Mayer, A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal. 9, 1221\u20131235 (2007).","journal-title":"Antioxid. Redox Signal."},{"key":"1107_CR14","doi-asserted-by":"crossref","first-page":"e1254","DOI":"10.21769\/BioProtoc.1254","volume":"4","author":"K Aguilera","year":"2014","unstructured":"Aguilera, K. & Brekken, R. Hypoxia studies with pimonidazole in vivo. Bio-Protoc. 4, e1254 (2014).","journal-title":"Bio-Protoc."},{"key":"1107_CR15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5732\/cjc.012.10285","volume":"33","author":"CP Guise","year":"2014","unstructured":"Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W. H., Wu, D. H. et al. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin. J. Cancer 33, 80\u201386 (2014).","journal-title":"Chin. J. Cancer"},{"key":"1107_CR16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.2011.35.9315","volume":"30","author":"GO Janssens","year":"2012","unstructured":"Janssens, G. O., Rademakers, S. E., Terhaard, C. H., Doornaert, P. A., Bijl, H. P., Van Ende, P. et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J. Clin. Oncol. 30, 1777\u20131783 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","volume":"114","author":"FW Hunter","year":"2016","unstructured":"Hunter, F. W., Wouters, B. G. & Wilson, W. R. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br. J. Cancer 114, 1071\u20131077 (2016).","journal-title":"Br. J. Cancer"},{"key":"1107_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito, L. & Semenza, G. L. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2, 758\u2013770 (2016).","journal-title":"Trends Cancer"},{"key":"1107_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","volume":"27","author":"H Choudhry","year":"2018","unstructured":"Choudhry, H. & Harris, A. L. Advances in hypoxia-inducible factor biology. Cell Metab. 27, 281\u2013298 (2018).","journal-title":"Cell Metab."},{"key":"1107_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-017-2701-1","volume":"372","author":"S P\u00e5hlman","year":"2018","unstructured":"P\u00e5hlman, S. & Mohlin, S. Hypoxia and hypoxia-inducible factors in neuroblastoma. Cell Tissue Res. 372, 269\u2013275 (2018).","journal-title":"Cell Tissue Res."},{"key":"1107_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13018-018-1031-7","volume":"14","author":"D Luo","year":"2019","unstructured":"Luo, D., Ren, H., Zhang, W., Xian, H., Lian, K. & Liu, H. Clinicopathological and prognostic value of hypoxia-inducible factor-1 \u03b1 in patients with bone tumor: a systematic review and meta- analysis. J. Orthop. Surg. Res. 14, 1\u201312 (2019).","journal-title":"J. Orthop. Surg. Res."},{"key":"1107_CR22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00428-012-1370-4","volume":"462","author":"P Ramani","year":"2013","unstructured":"Ramani, P., Headford, A. & May, M. T. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch. 462, 203\u2013209 (2013).","journal-title":"Virchows Arch."},{"key":"1107_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0083701","volume":"8","author":"HM Ameis","year":"2013","unstructured":"Ameis, H. M., Drenckhan, A., Von Loga, K., Escherich, G., Wenke, K., Izbicki, J. R. et al. PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma. PLoS ONE 8, 1\u20138 (2013).","journal-title":"PLoS ONE"},{"key":"1107_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00383-015-3831-8","volume":"32","author":"HM Ameis","year":"2016","unstructured":"Ameis, H. M., Drenckhan, A., Freytag, M., Izbicki, J. R., Supuran, C. T. & Reinshagen, K. Influence of hypoxia-dependent factors on the progression of neuroblastoma. Pediatr. Surg. Int. 32, 187\u2013192 (2016).","journal-title":"Pediatr. Surg. Int."},{"key":"1107_CR25","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.2147\/OTT.S177605","volume":"11","author":"K Okuno","year":"2018","unstructured":"Okuno, K., Matsubara, T., Nakamura, T., Iino, T., Kakimoto, T., Asanuma, K. et al. Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma. Onco. Targets Ther. 11, 6879\u20136886 (2018).","journal-title":"Onco. Targets Ther."},{"key":"1107_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exer.2017.07.001","volume":"162","author":"Q Yang","year":"2017","unstructured":"Yang, Q., Tripathy, A., Yu, W., Eberhart, C. G. & Asnaghi, L. Hypoxia inhibits growth, proliferation, and increases response to chemotherapy in retinoblastoma cells. Exp. Eye Res. 162, 48\u201361 (2017).","journal-title":"Exp. Eye Res."},{"key":"1107_CR27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/1354750X.2019.1606275","volume":"24","author":"MA Krawczyk","year":"2019","unstructured":"Krawczyk, M. A., Styczewska, M., Sokolewicz, E. M., Kunc, M., Gabrych, A., Fatyga, A. et al. Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma. Biomarkers 24, 538\u2013548 (2019).","journal-title":"Biomarkers"},{"key":"1107_CR28","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1089\/ars.2013.5378","volume":"21","author":"JC Walsh","year":"2014","unstructured":"Walsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L. & Kolb, H. C. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis. Antioxid. Redox Signal. 21, 1516\u20131554 (2014).","journal-title":"Antioxid. Redox Signal."},{"key":"1107_CR29","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-10-132","volume":"10","author":"M Bache","year":"2010","unstructured":"Bache, M., Kappler, M., Wichmann, H., Rot, S., Hahnel, A., Greither, T. et al. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10, 132 (2010).","journal-title":"BMC Cancer"},{"key":"1107_CR30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(05)70292-8","volume":"6","author":"J Overgaard","year":"2005","unstructured":"Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J. & Horsman, M. R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 6, 757\u2013764 (2005).","journal-title":"Lancet Oncol."},{"key":"1107_CR31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/bmm-2016-0308","volume":"11","author":"G Karpinsky","year":"2017","unstructured":"Karpinsky, G., Fatyga, A., Krawczyk, M. A., Chamera, M., Sande, N., Szmyd, D. et al. Osteopontin: its potential role in cancer of children and young adults. Biomark. Med. 11, 389\u2013402 (2017).","journal-title":"Biomark. Med."},{"key":"1107_CR32","first-page":"2592","volume":"17","author":"X Han","year":"2019","unstructured":"Han, X., Wang, W., He, J., Jiang, L. & Li, X. Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review). Oncol. Lett. 17, 2592\u20132598 (2019).","journal-title":"Oncol. Lett."},{"key":"1107_CR33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clon.2015.07.004","volume":"27","author":"BHL Harris","year":"2015","unstructured":"Harris, B. H. L., Barberis, A., West, C. M. L. & Buffa, F. M. Gene expression signatures as biomarkers of tumour hypoxia. Clin. Oncol. 27, 547\u2013560 (2015).","journal-title":"Clin. Oncol."},{"key":"1107_CR34","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-11-1182","volume":"71","author":"K Toustrup","year":"2011","unstructured":"Toustrup, K., S\u00f8rensen, B. S., Nordsmark, M., Busk, M., Wiuf, C., Alsner, J. et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 71, 5923\u20135932 (2011).","journal-title":"Cancer Res"},{"key":"1107_CR35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/sj.bjc.6605450","volume":"102","author":"FM Buffa","year":"2010","unstructured":"Buffa, F. M., Harris, A. L., West, C. M. & Miller, C. J. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J. Cancer 102, 428\u2013435 (2010).","journal-title":"Br. J. Cancer"},{"key":"1107_CR36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2018.04.019","volume":"31","author":"L Yang","year":"2018","unstructured":"Yang, L., Roberts, D., Takhar, M., Erho, N., Bibby, B. A. S., Thiruthaneeswaran, N. et al. Development and validation of a 28-gene hypoxia-related prognostic signature for localized prostate cancer. EBioMedicine 31, 182\u2013189 (2018).","journal-title":"EBioMedicine"},{"key":"1107_CR37","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-17-0038","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L., Taylor, J., Eustace, A., Irlam, J. J., Denley, H., Hoskin, P. J. et al. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients. Clin. Cancer Res. 23, 4761\u20134768 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR38","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.18632\/oncotarget.23280","volume":"9","author":"L Yang","year":"2018","unstructured":"Yang, L., Forker, L., Irlam, J. J., Pillay, N., Choudhury, A. & West, C. M. L. Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. Oncotarget 9, 3946\u20133955 (2018).","journal-title":"Oncotarget"},{"key":"1107_CR39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ctro.2019.09.006","volume":"19","author":"J Lukovic","year":"2019","unstructured":"Lukovic, J., Han, K., Pintilie, M., Chaudary, N., Hill, R. P., Fyles, A. et al. Intratumoral heterogeneity and hypoxia gene expression signatures: is a single biopsy adequate? Clin. Transl. Radiat. Oncol. 19, 110\u2013115 (2019).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"1107_CR40","doi-asserted-by":"crossref","first-page":"76816","DOI":"10.18632\/oncotarget.12713","volume":"7","author":"MA Applebaum","year":"2016","unstructured":"Applebaum, M. A., Jha, A. R., Kao, C., Hernandez, K. M., Salwen, H. R., Chlenski, A. et al. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget 7, 76816\u201376826 (2016).","journal-title":"Oncotarget"},{"key":"1107_CR41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2012.171","volume":"9","author":"MR Horsman","year":"2012","unstructured":"Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M. & Overgaard, J. Imaging hypoxia to improve radiotherapy outcome. Nat. Rev. Clin. Oncol. 9, 674\u2013687 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1107_CR42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clon.2014.02.002","volume":"26","author":"EM Hammond","year":"2014","unstructured":"Hammond, E. M., Asselin, M. C., Forster, D., O\u2019Connor, J. P. B., Senra, J. M. & Williams, K. J. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin. Oncol. 26, 277\u2013288 (2014).","journal-title":"Clin. Oncol."},{"key":"1107_CR43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/0008-5472.CAN-15-2818","volume":"76","author":"MW Dewhirst","year":"2016","unstructured":"Dewhirst, M. W. & Birer, S. R. Oxygen-enhanced MRI is a major advance in tumor hypoxia imaging. Cancer Res. 76, 769\u2013772 (2016).","journal-title":"Cancer Res."},{"key":"1107_CR44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejca.2016.10.037","volume":"72","author":"KA Manias","year":"2017","unstructured":"Manias, K. A., Gill, S. K., MacPherson, L., Foster, K., Oates, A. & Peet, A. C. Magnetic resonance imaging based functional imaging in paediatric oncology. Eur. J. Cancer 72, 251\u2013265 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1107_CR45","doi-asserted-by":"crossref","unstructured":"Rickard, A. G., Palmer, G. M. & Dewhirst, M. W. In Hypoxia and Cancer Metastasis (ed. Gilkes, D. M.) Springer, Cham, 19\u201341 (2019).","DOI":"10.1007\/978-3-030-12734-3_2"},{"key":"1107_CR46","doi-asserted-by":"crossref","first-page":"20180642","DOI":"10.1259\/bjr.20180642","volume":"92","author":"JPB O\u2019Connor","year":"2019","unstructured":"O\u2019Connor, J. P. B., Robinson, S. P. & Waterton, J. C. Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. Br. J. Radiol. 92, 20180642 (2019).","journal-title":"Br. J. Radiol."},{"key":"1107_CR47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1099-1492(199904)12:2<98::AID-NBM556>3.0.CO;2-I","volume":"12","author":"SP Robinson","year":"1999","unstructured":"Robinson, S. P., Collingridge, D. R., Howe, F. A., Rodrigues, L. M., Chaplin, D. J. & Griffiths, J. R. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed. 12, 98\u2013106 (1999).","journal-title":"NMR Biomed."},{"key":"1107_CR48","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/mrm.10318","volume":"48","author":"C Baudelet","year":"2002","unstructured":"Baudelet, C. & Gallez, B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn. Reson. Med. 48, 980\u2013986 (2002).","journal-title":"Magn. Reson. Med."},{"key":"1107_CR49","first-page":"1","volume":"30","author":"TT Cao-Pham","year":"2017","unstructured":"Cao-Pham, T. T., Joudiou, N., Van Hul, M., Bouzin, C., Cani, P. D., Gallez, B. et al. Combined endogenous MR biomarkers to predict basal tumor oxygenation and response to hyperoxic challenge. NMR Biomed. 30, 1\u201312 (2017).","journal-title":"NMR Biomed."},{"key":"1107_CR50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nbm.728","volume":"15","author":"HA Al-Hallaq","year":"2002","unstructured":"Al-Hallaq, H. A., Fan, X., Zamora, M., River, J. N., Moulder, J. E. & Karczmar, G. S. Spectrally inhomogeneous BOLD contrast changes detected in rodent tumors with high spectral and spatial resolution MRI. NMR Biomed. 15, 28\u201330 (2002).","journal-title":"NMR Biomed."},{"key":"1107_CR51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1148\/radiol.12120128","volume":"266","author":"Y Jamin","year":"2013","unstructured":"Jamin, Y., Tucker, E. R., Poon, E., Popov, S., Vaughan, L., Boult, J. K. R. et al. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology 266, 130\u2013140 (2013).","journal-title":"Radiology"},{"key":"1107_CR52","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nm1196-1236","volume":"2","author":"RR Edelman","year":"1996","unstructured":"Edelman, R. R., Hatabu, H., Tadamura, E., Li, W. & Prasad, P. V. Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nat. Med. 2, 1236\u20131239 (1996).","journal-title":"Nat. Med."},{"key":"1107_CR53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/0008-5472.CAN-15-2062","volume":"76","author":"JPB O\u2019Connor","year":"2016","unstructured":"O\u2019Connor, J. P. B., Boult, J. K. R., Jamin, Y., Babur, M., Finegan, K. G., Williams, K. J. et al. Oxygen-enhanced MRI accurately identifies, quantifies, and maps tumor hypoxia in preclinical cancer models. Cancer Res. 76, 787\u2013795 (2016).","journal-title":"Cancer Res."},{"key":"1107_CR54","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/mrm.27584","volume":"81","author":"F Moosvi","year":"2019","unstructured":"Moosvi, F., Baker, J. H. E., Yung, A., Kozlowski, P., Minchinton, A. I. & Reinsberg, S. A. Fast and sensitive dynamic oxygen-enhanced MRI with a cycling gas challenge and independent component analysis. Magn. Reson. Med. 81, 2514\u20132525 (2019).","journal-title":"Magn. Reson. Med."},{"key":"1107_CR55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1148\/radiol.2018171531","volume":"288","author":"RA Little","year":"2018","unstructured":"Little, R. A., Jamin, Y., Boult, J. K. R., Naish, J. H., Watson, Y., Cheung, S. et al. Mapping hypoxia in renal carcinoma with oxygen-enhanced MRI: comparison with intrinsic susceptibility MRI and pathology. Radiology 288, 739\u2013747 (2018).","journal-title":"Radiology"},{"key":"1107_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2018.00001","volume":"8","author":"LCJ Baker","year":"2018","unstructured":"Baker, L. C. J., Sikka, A., Price, J. M., Boult, J. K. R., Lepicard, E. Y., Box, G. et al. Evaluating imaging biomarkers of acquired resistance to targeted EGFR therapy in xenograft models of human head and neck squamous cell carcinoma. Front. Oncol. 8, 1\u201310 (2018).","journal-title":"Front. Oncol."},{"key":"1107_CR57","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-18-3932","volume":"25","author":"A Salem","year":"2019","unstructured":"Salem, A., Little, R. A., Latif, A., Featherstone, A. K., Babur, M., Peset, I. et al. Oxygen-enhanced MRI is feasible, repeatable, and detects radiotherapy-induced change in hypoxia in xenograft models and in patients with non-small cell lung cancer. Clin. Cancer Res. 25, 3818\u20133829 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/09553000903043059","volume":"85","author":"S Chopra","year":"2009","unstructured":"Chopra, S., Foltz, W. D., Milosevic, M. F., Toi, A., Bristow, R. G., M\u00e9nard, C. et al. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int. J. Radiat. Biol. 85, 805\u2013813 (2009).","journal-title":"Int. J. Radiat. Biol."},{"key":"1107_CR59","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & De Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346\u2013354 (2013).","journal-title":"Nature"},{"key":"1107_CR60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrclinonc.2017.59","volume":"14","author":"L Moreno","year":"2017","unstructured":"Moreno, L., Pearson, A. D. J., Paoletti, X., Jimenez, I., Geoerger, B., Kearns, P. R. et al. Early phase clinical trials of anticancer agents in children and adolescents-an ITCC perspective. Nat. Rev. Clin. Oncol. 14, 497\u2013507 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1107_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2776-1","volume":"16","author":"C Petit","year":"2016","unstructured":"Petit, C., Gouel, F., Dubus, I., Heuclin, C., Roget, K. & Vannier, J. P. Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways. BMC Cancer 16, 1\u201317 (2016).","journal-title":"BMC Cancer"},{"key":"1107_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5476-9","volume":"19","author":"S Cowman","year":"2019","unstructured":"Cowman, S., Fan, Y. N., Pizer, B. & S\u00e9e, V. Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells. BMC Cancer 19, 1\u201316 (2019).","journal-title":"BMC Cancer"},{"key":"1107_CR63","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/sj.onc.1210008","volume":"26","author":"M Kilic","year":"2007","unstructured":"Kilic, M., Kasperczyk, H., Fulda, S. & Debatin, K. M. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26, 2027\u20132038 (2007).","journal-title":"Oncogene"},{"key":"1107_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours\u2014implications for treatment response. Br. J. Radiol. 87, 1\u201312 (2014).","journal-title":"Br. J. Radiol."},{"key":"1107_CR65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00000421-200110000-00009","volume":"24","author":"B Movsas","year":"2001","unstructured":"Movsas, B., Chapman, J. D., Hanlon, A. L., Horwitz, E. M., Pinover, W. H., Greenberg, R. E. et al. Hypoxia in human prostate carcinoma. An eppendorf PO2 study. Am. J. Clin. Oncol. 24, 458\u2013461 (2001).","journal-title":"Am. J. Clin. Oncol."},{"key":"1107_CR66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/028418601750071163","volume":"40","author":"S Graffman","year":"2001","unstructured":"Graffman, S., Bj\u00f6rk, P., Ederoth, P. & Ihse, I. Polarographic pO2 measurements of intra-abdominal adenocarcinoma in connection with intraoperative radiotherapy before and after change of oxygen concentration of anaesthetic gases [1]. Acta Oncol. 40, 105\u2013107 (2001).","journal-title":"Acta Oncol."},{"key":"1107_CR67","unstructured":"Kallinowski, F. & Buhr, H. J. In Tumor Oxyg. (eds Vaupel, P., Kelleher, D. & G\u00fcnderoth, M.) 205\u2013209 (Gustav Fischer, 1995)."},{"key":"1107_CR68","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/cbt.20838","volume":"13","author":"O Frolova","year":"2012","unstructured":"Frolova, O., Samudio, I., Benito, J., Jacamo, R., Kornblau, S. M., Markovic, A. et al. Regulation of HIF-1\u03b1 signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol. Ther. 13, 858\u2013870 (2012).","journal-title":"Cancer Biol. Ther."},{"key":"1107_CR69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1568009617666170315162525","volume":"18","author":"GAV Cruzeiro","year":"2018","unstructured":"Cruzeiro, G. A. V., dos Reis, M. B., Silveira, V. S., Lira, R. C. P., Carlotti Jr, C. G., Neder, L. et al. HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation. Curr. Cancer Drug Targets 18, 287\u2013294 (2018).","journal-title":"Curr. Cancer Drug Targets"},{"key":"1107_CR70","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-09-4333","volume":"70","author":"DNT Aryee","year":"2010","unstructured":"Aryee, D. N. T., Niedan, S., Kauer, M., Schwentner, R., Bennani-Baiti, I. M., Ban, J. et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing\u2019s sarcoma cells in vitro. Cancer Res. 70, 4015\u20134023 (2010).","journal-title":"Cancer Res."},{"key":"1107_CR71","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.neo.2016.06.008","volume":"18","author":"KM Bailey","year":"2016","unstructured":"Bailey, K. M., Airik, M., Krook, M. A., Pedersen, E. A. & Lawlor, E. R. Micro-environmental stress induces Src-dependent activation of invadopodia and cell migration in Ewing sarcoma. Neoplasia 18, 480\u2013488 (2016).","journal-title":"Neoplasia"},{"key":"1107_CR72","unstructured":"Nilan, R. A. A conference on radioactive isotopes in agricultures. In Factors Gov. Plant Radiosensitivity (United States Atomic Energy Comission, 1956)."},{"key":"1107_CR73","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","volume":"XXVI","author":"LH Gray","year":"1953","unstructured":"Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S. & Scott, O. C. A. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. XXVI, 638\u2013648 (1953).","journal-title":"Br. J. Radiol."},{"key":"1107_CR74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bjc.1955.55","volume":"9","author":"RH Thomlinson","year":"1955","unstructured":"Thomlinson, R. H. & Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9, 539\u2013549 (1955).","journal-title":"Br. J. Cancer"},{"key":"1107_CR75","doi-asserted-by":"crossref","unstructured":"Horsman, M. R., Lindegaard, J. C., Grau, C., Nordsmark, M., Alsner, J. & Overgaard, J. Dose-response modifiers in radiation therapy. In Clinical Radiation Oncology (Elsevier Inc., 2015).","DOI":"10.1016\/B978-0-323-24098-7.00003-4"},{"key":"1107_CR76","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","volume":"28","author":"PJ Hoskin","year":"2010","unstructured":"Hoskin, P. J., Rojas, A. M., Bentzen, S. M. & Saunders, M. I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J. Clin. Oncol. 28, 4912\u20134918 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR77","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1158\/1078-0432.CCR-13-0542","volume":"19","author":"A Eustace","year":"2013","unstructured":"Eustace, A., Mani, N., Span, P. N., Irlam, J. J., Taylor, J., Betts, G. N. J. et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin. Cancer Res. 19, 4879\u20134888 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR78","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijrobp.2010.11.045","volume":"82","author":"GO Janssens","year":"2012","unstructured":"Janssens, G. O., Terhaard, C. H., Doornaert, P. A., Bijl, H. P., Van Den Ende, P., Chin, A. et al. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 82, 532\u2013538 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1107_CR79","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ejpn.2016.04.001","volume":"20","author":"R Forsyth","year":"2016","unstructured":"Forsyth, R., Martland, T., Lai, M., Vadlamani, G. & Hogan, V. 5% carbon dioxide is safe but of limited efficacy as a treatment for paediatric non-convulsive status epilepticus: an open label observational study. Eur. J. Paediatr. Neurol. 20, 560\u2013565 (2016).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1107_CR80","doi-asserted-by":"crossref","unstructured":"Yang, X. F., Shi, X. Y., Ju, J., Zhang, W. N., Liu, Y. J., Li, X. Y. & Zou, L. P. 5% CO2 inhalation suppresses hyperventilation-induced absence seizures in children. Epilepsy Res. 108, 345\u2013348 (2014).","DOI":"10.1016\/j.eplepsyres.2013.11.012"},{"key":"1107_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-11-157","volume":"11","author":"S Ohlraun","year":"2013","unstructured":"Ohlraun, S., Wollersheim, T., Wei\u00df, C., Martus, P., Weber-Carstens, S., Schmitz, D. et al. Carbon dioxide for the treatment of febrile seizures: rationale, feasibility, and design of the CARDIF-study. J. Transl. Med. 11, 1\u20139 (2013).","journal-title":"J. Transl. Med."},{"key":"1107_CR82","doi-asserted-by":"crossref","unstructured":"Aquino-Parsons, C., Hukin, J. & Green, A. Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas. Pediatr. Blood Cancer 50, 397\u2013399 (2006).","DOI":"10.1002\/pbc.21057"},{"key":"1107_CR83","first-page":"1","volume":"92","author":"JT Coates","year":"2019","unstructured":"Coates, J. T., Skwarski, M. & Higgins, G. S. Targeting tumour hypoxia: shifting focus from oxygen supply to demand. Br. J. Radiol. 92, 1\u20133 (2019).","journal-title":"Br. J. Radiol."},{"key":"1107_CR84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/02841869509093981","volume":"34","author":"TW Secomb","year":"1995","unstructured":"Secomb, T. W., Hsu, R., Ong, E. T., Gross, J. F. & Dewhirst, M. W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 34, 313\u2013316 (1995).","journal-title":"Acta Oncol."},{"key":"1107_CR85","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1158\/1078-0432.CCR-13-1787","volume":"19","author":"VE Zannella","year":"2013","unstructured":"Zannella, V. E., Pra, A. D., Muaddi, H., McKee, T. D., Stapleton, S., Sykes, J. et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res. 19, 6741\u20136750 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR86","first-page":"2431","volume":"17","author":"H Fujita","year":"2019","unstructured":"Fujita, H., Hirose, K., Sato, M., Fujioka, I., Fujita, T., Aoki, M. et al. Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line. Oncol. Lett. 17, 2431\u20132440 (2019).","journal-title":"Oncol. Lett."},{"key":"1107_CR87","first-page":"1","volume":"8","author":"C Garofalo","year":"2013","unstructured":"Garofalo, C., Capristo, M., Manara, M. C., Mancarella, C., Landuzzi, L., Belfiore, A. et al. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. PLoS ONE 8, 1\u201312 (2013).","journal-title":"PLoS ONE"},{"key":"1107_CR88","doi-asserted-by":"crossref","unstructured":"Schulten, H. J. Pleiotropic effects of metformin on cancer. Int. J. Mol. Sci. 19, 2850 (2018).","DOI":"10.3390\/ijms19102850"},{"key":"1107_CR89","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OTT.S170585","volume":"12","author":"D Van Mater","year":"2019","unstructured":"Van Mater, D. & Wagner, L. Management of recurrent Ewing sarcoma: challenges and approaches. Onco. Targets Ther. 12, 2279\u20132288 (2019).","journal-title":"Onco. Targets Ther."},{"key":"1107_CR90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4172\/2161-0665.1000202","volume":"04","author":"M Goldberg","year":"2014","unstructured":"Goldberg, M., J & Panoff, J. Pediatric oncology drug development: a case report and pathways forward. Pediatr. Ther. 04, 4\u20136 (2014).","journal-title":"Pediatr. Ther."},{"key":"1107_CR91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12308","volume":"7","author":"TM Ashton","year":"2016","unstructured":"Ashton, T. M., Fokas, E., Kunz-Schughart, L. A., Folkes, L. K., Anbalagan, S., Huether, M. et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat. Commun. 7, 1\u201313 (2016).","journal-title":"Nat. Commun."},{"key":"1107_CR92","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cncr.22562","volume":"109","author":"RM Madden","year":"2007","unstructured":"Madden, R. M., Pui, C. H., Hughes, W. T., Flynn, P. M. & Leung, W. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 109, 1654\u20131658 (2007).","journal-title":"Cancer"},{"key":"1107_CR93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.drudis.2012.07.009","volume":"18","author":"J Blatt","year":"2013","unstructured":"Blatt, J. & Corey, S. J. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov. Today 18, 4\u201310 (2013).","journal-title":"Drug Discov. Today"},{"key":"1107_CR94","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/pr.118.016972","volume":"71","author":"PJ Houghton","year":"2019","unstructured":"Houghton, P. J. & Kurmasheva, R. T. Challenges and opportunities for childhood cancer drug development. Pharmacol. Rev. 71, 671\u2013697 (2019).","journal-title":"Pharmacol. Rev."},{"key":"1107_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00001","volume":"9","author":"CR Hong","year":"2018","unstructured":"Hong, C. R., Bogle, G., Wang, J., Patel, K., Pruijn, F. B., Wilson, W. R. et al. Bystander effects of hypoxia-activated prodrugs: agent-based modeling using three dimensional cell cultures. Front. Pharmacol. 9, 1\u201316 (2018).","journal-title":"Front. Pharmacol."},{"key":"1107_CR96","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","volume":"13","author":"AV Patterson","year":"2007","unstructured":"Patterson, A. V., Ferry, D. M., Edmunds, S. J., Gu, Y., Singleton, R. S., Patel, K. et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res. 13, 3922\u20133932 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR97","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","volume":"70","author":"CP Guise","year":"2010","unstructured":"Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U. et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70, 1573\u20131584 (2010).","journal-title":"Cancer Res."},{"key":"1107_CR98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neo.2018.11.009","volume":"21","author":"CR Hong","year":"2019","unstructured":"Hong, C. R., Wilson, W. R. & Hicks, K. O. An intratumor pharmacokinetic\/pharmacodynamic model for the hypoxia-activated prodrug evofosfamide (TH-302): monotherapy activity is not dependent on a bystander effect. Neoplasia 21, 159\u2013171 (2019).","journal-title":"Neoplasia"},{"key":"1107_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-018-0270-7","volume":"38","author":"Y Huang","year":"2018","unstructured":"Huang, Y., Tian, Y., Zhao, Y., Xue, C., Zhan, J., Liu, L. et al. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. Cancer Commun. 38, 1\u20139 (2018).","journal-title":"Cancer Commun."},{"key":"1107_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells8070717","volume":"8","author":"JK Harms","year":"2019","unstructured":"Harms, J. K., Lee, T.-W., Wang, T., Lai, A., Kee, D., Chaplin, J. M. et al. Impact of tumour hypoxia on evofosfamide sensitivity in head and neck squamous cell carcinoma patient-derived xenograft models. Cells 8, 1\u201318 (2019).","journal-title":"Cells"},{"key":"1107_CR101","doi-asserted-by":"crossref","unstructured":"Foehrenbacher, A., Secomb, T. W., Wilson, W. R. & Hicks, K. O. Design of optimized hypoxia-activated prodrugs using pharmacokinetic\/pharmacodynamic modeling. Front. Oncol. 314, 33\u201335 (2013).","DOI":"10.3389\/fonc.2013.00314"},{"key":"1107_CR102","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","volume":"98","author":"IN Mistry","year":"2017","unstructured":"Mistry, I. N., Thomas, M., Calder, E. D. D., Conway, S. J. & Hammond, E. M. Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy. Radiat. Oncol. Biol. 98, 1183\u20131196 (2017).","journal-title":"Radiat. Oncol. Biol."},{"key":"1107_CR103","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0167-8140(85)80015-3","volume":"3","author":"S Dische","year":"1985","unstructured":"Dische, S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother. Oncol. 3, 97\u2013115 (1985).","journal-title":"Radiother. Oncol."},{"key":"1107_CR104","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.1982.300","volume":"46","author":"J Overgaard","year":"1982","unstructured":"Overgaard, J., Overgaard, M., Nielsen, O. S., Pedersen, A. K. & Timothy, A. R. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br. J. Cancer 46, 904\u2013911 (1982).","journal-title":"Br. J. Cancer"},{"key":"1107_CR105","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","volume":"25","author":"J Overgaard","year":"2019","unstructured":"Overgaard, J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25, 4066\u20134074 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR106","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clon.2014.03.003","volume":"26","author":"D Thomson","year":"2014","unstructured":"Thomson, D., Yang, H., Baines, H., Miles, E., Bolton, S., West, C. et al. NIMRAD\u2014a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin. Oncol. 26, 344\u2013347 (2014).","journal-title":"Clin. Oncol."},{"key":"1107_CR107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1593\/tlo.11166","volume":"4","author":"BT Oronsky","year":"2011","unstructured":"Oronsky, B. T., Knox, S. J. & Scicinski, J. Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl. Oncol. 4, 189\u2013198 (2011).","journal-title":"Transl. Oncol."},{"key":"1107_CR108","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","volume":"32","author":"PA Disilvestro","year":"2014","unstructured":"Disilvestro, P. A., Ali, S., Craighead, P. S., Lucci, J. A., Lee, Y., Cohn, D. E. et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a gynecologic oncology group study. J. Clin. Oncol. 32, 458\u2013464 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR109","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","volume":"28","author":"D Rischin","year":"2010","unstructured":"Rischin, D., Peters, L. J., O\u2019Sullivan, B., Giralt, J., Fisher, R., Yuen, K. et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the trans-tasman radiation oncology group. J. Clin. Oncol. 28, 2989\u20132995 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR110","doi-asserted-by":"crossref","unstructured":"Spiegelberg, L., Hoof, S. J. Van, Biemans, R., Lieuwes, N. G., Marcus, D., Niemans, R. et al. Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. Radiother. Oncol. 141, 247\u2013255 (2019).","DOI":"10.1016\/j.radonc.2019.06.034"},{"key":"1107_CR111","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1158\/1078-0432.CCR-15-0018","volume":"21","author":"SGJA Peeters","year":"2015","unstructured":"Peeters, S. G. J. A., Zegers, C. M. L., Biemans, R., Lieuwes, N. G., Stiphout, R. G. P. M., Van, Yaromina, A. et al. TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin. Cancer Res. 21, 2984\u20132993 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR112","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","volume":"77","author":"RM Phillips","year":"2016","unstructured":"Phillips, R. M. Targeting the hypoxic fraction of tumours using hypoxia\u2011activated prodrugs. Cancer Chemother. Pharmacol. 77, 441\u2013457 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1107_CR113","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/1078-0432.CCR-15-1853","volume":"22","author":"L Zhang","year":"2016","unstructured":"Zhang, L., Marrano, P., Wu, B., Kumar, S., Thorner, P. & Baruchel, S. Combined antitumor therapy with metronomic topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma and rhabdomyosarcoma preclinical models. Clin. Cancer Res. 22, 2697\u20132708 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR114","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2004.07.111","volume":"22","author":"VM Aquino","year":"2004","unstructured":"Aquino, V. M., Weitman, S. D., Winick, N. J., Blaney, S., Furman, W. L., Kepner, J. L. et al. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J. Clin. Oncol. 22, 1413\u20131419 (2004).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR115","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/cncr.32122","volume":"125","author":"L Mascarenhas","year":"2019","unstructured":"Mascarenhas, L., Lyden, E. R., Breitfeld, P. P., Walterhouse, D. O., Donaldson, S. S., Rodeberg, D. A. et al. Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: a report from the children\u2019s oncology group. Cancer 125, 2602\u20132609 (2019).","journal-title":"Cancer"},{"key":"1107_CR116","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","volume":"32","author":"SP Chawla","year":"2014","unstructured":"Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E. et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J. Clin. Oncol. 32, 3299\u20133306 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR117","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","volume":"18","author":"WD Tap","year":"2017","unstructured":"Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L. et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 18, 1089\u20131103 (2017).","journal-title":"Lancet Oncol."},{"key":"1107_CR118","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","volume":"40","author":"AJ Majmundar","year":"2010","unstructured":"Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294\u2013309 (2010).","journal-title":"Mol. Cell"},{"key":"1107_CR119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H. et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18, 1\u201315 (2019).","journal-title":"Mol. Cancer"},{"key":"1107_CR120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","volume":"300","author":"M Garcia-Barros","year":"2003","unstructured":"Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155\u20131159 (2003).","journal-title":"Science"},{"key":"1107_CR121","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1535-6108(04)00115-1","volume":"5","author":"BJ Moeller","year":"2004","unstructured":"Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429\u2013441 (2004).","journal-title":"Cancer Cell"},{"key":"1107_CR122","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","volume":"164","author":"C Wigerup","year":"2016","unstructured":"Wigerup, C., P\u00e5hlman, S. & Bexell, D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol. Ther. 164, 152\u2013169 (2016).","journal-title":"Pharmacol. Ther."},{"key":"1107_CR123","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-06-1892","volume":"13","author":"R Bagatell","year":"2007","unstructured":"Bagatell, R., Gore, L., Egorin, M. J., Ho, R., Heller, G., Boucher, N. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycinin pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin. Cancer Res. 13, 1783\u20131788 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR124","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1078-0432.CCR-06-2270","volume":"13","author":"BJ Weigel","year":"2007","unstructured":"Weigel, B. J., Blaney, S. M., Reid, J. M., Safgren, S. L., Bagatell, R., Kersey, J. et al. A phase I study of 17-allylaminogeldanamycin in relapsed\/refractory pediatric patients with solid tumors: a children\u2019s oncology group study. Clin. Cancer Res. 13, 1789\u20131793 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/0284186X.2017.1301680","volume":"56","author":"S Soni","year":"2017","unstructured":"Soni, S. & Padwad, Y. S. HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol. 56, 503\u2013515 (2017).","journal-title":"Acta Oncol."},{"key":"1107_CR126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2017.01.013","volume":"111","author":"O Mart\u00ednez-S\u00e1ez","year":"2017","unstructured":"Mart\u00ednez-S\u00e1ez, O., Gajate Borau, P., Alonso-Gordoa, T., Molina-Cerrillo, J. & Grande, E. Targeting HIF-2 \u03b1 in clear cell renal cell carcinoma: a promising therapeutic strategy. Crit. Rev. Oncol. Hematol. 111, 117\u2013123 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1107_CR127","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.drudis.2019.09.008","volume":"24","author":"Y Yu","year":"2019","unstructured":"Yu, Y., Yu, Q. & Zhang, X. Allosteric inhibition of HIF-2\u03b1 as a novel therapy for clear cell renal cell carcinoma. Drug Discov. Today 24, 2332\u20132340 (2019).","journal-title":"Drug Discov. Today"},{"key":"1107_CR128","doi-asserted-by":"crossref","first-page":"111845","DOI":"10.1016\/j.yexcr.2020.111845","volume":"388","author":"CU Persson","year":"2020","unstructured":"Persson, C. U., von Stedingk, K., Fredlund, E., Bexell, D., P\u00e5hlman, S., Wigerup, C. et al. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma. Exp. Cell Res. 388, 111845 (2020).","journal-title":"Exp. Cell Res."},{"key":"1107_CR129","doi-asserted-by":"crossref","first-page":"E6137","DOI":"10.1073\/pnas.1700655114","volume":"114","author":"I Westerlund","year":"2017","unstructured":"Westerlund, I., Shi, Y., Toskas, K., Fell, S. M., Li, S., Surova, O. et al. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2\u03b1 to tumor suppression. Proc. Natl Acad. Sci. USA 114, E6137\u2013E6146 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1107_CR130","first-page":"178","volume":"41","author":"J Valencia-Cervantes","year":"2019","unstructured":"Valencia-Cervantes, J., Huerta-Yepez, S., AquIno-Jarqui\u0301n, G., Rodri\u0301guez-Enri\u0301quez, S., Marti\u0301nez-Fong, D., Arias-Montan\u0303o, J.-A. et al. Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia\u2011inducible factor 1\u03b1\u2011mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation. Oncol. Rep. 41, 178\u2013190 (2019).","journal-title":"Oncol. Rep."},{"key":"1107_CR131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2018.00328","volume":"6","author":"M Papale","year":"2018","unstructured":"Papale, M., Ferretti, E., Battaglia, G., Bellavia, D., Mai, A. & Tafani, M. EZH2, HIF-1, and their inhibitors: an overview on pediatric cancers. Front. Pediatr. 6, 1\u201313 (2018).","journal-title":"Front. Pediatr."},{"key":"1107_CR132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-14990-w","volume":"7","author":"A Mangraviti","year":"2017","unstructured":"Mangraviti, A., Ra, T., Volpin, F., Skuli, N., Gullotti, D., Zho, J. et al. HIF-1 \u03b1-targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Sci. Rep. 7, 1\u201313 (2017).","journal-title":"Sci. Rep."},{"key":"1107_CR133","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-08-0981","volume":"8","author":"DL Schwartz","year":"2009","unstructured":"Schwartz, D. L., Powis, G., Thitai-Kumar, A., He, Y., Bankson, J., Williams, R. et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol. Cancer Ther. 8, 947\u2013958 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"1107_CR134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2019.00004","volume":"7","author":"W Al Tameemi","year":"2019","unstructured":"Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K. & Forsyth, N. R. Hypoxia-modified cancer cell metabolism. Front. Cell Dev. Biol. 7, 1\u201315 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"1107_CR135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10456-017-9546-9","volume":"20","author":"LC Hamming","year":"2017","unstructured":"Hamming, L. C., Slotman, B. J., Verheul, H. M. W. & Thijssen, V. L. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis 20, 217\u2013232 (2017).","journal-title":"Angiogenesis"},{"key":"1107_CR136","doi-asserted-by":"crossref","first-page":"20180405","DOI":"10.1259\/bjr.20180405","volume":"92","author":"C Kanthou","year":"2019","unstructured":"Kanthou, C. & Tozer, G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. Br. J. Radiol. 92, 20180405 (2019).","journal-title":"Br. J. Radiol."},{"key":"1107_CR137","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709\u2013722 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR138","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699\u2013708 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR139","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/2211552811201030169","volume":"1","author":"B Schmidt","year":"2012","unstructured":"Schmidt, B., Lee, H.-J., Ryeom, S. & Yoon, S. Combining bevacizumab with radiation or chemoradiation for solid tumors: a review of the scientific rationale, and clinical trials. Curr. Angiogenes. 1, 169\u2013179 (2012).","journal-title":"Curr. Angiogenes."},{"key":"1107_CR140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","volume":"26","author":"JLG Bender","year":"2008","unstructured":"Bender, J. L. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y. et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children\u2019 s oncology group study. J. Clin. Oncol. 26, 399\u2013405 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR141","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2020.01.029","volume":"130","author":"A Ferrari","year":"2020","unstructured":"Ferrari, A., Merks, J. H. M., Chisholm, J. C., Orbach, D., Brennan, B., Gallego, S. et al. Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. Eur. J. Cancer 130, 72\u201380 (2020).","journal-title":"Eur. J. Cancer"},{"key":"1107_CR142","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","volume":"28","author":"S Gururangan","year":"2010","unstructured":"Gururangan, S., Chi, S. N., Poussaint, T. Y., Onar-thomas, A., Gilbertson, R. J., Vajapeyam, S. et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J. Clin. Oncol. 28, 3069\u20133075 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR143","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/neuonc\/not154","volume":"16","author":"S Gururangan","year":"2014","unstructured":"Gururangan, S., Fangusaro, J., Poussaint, T. Y., McLendon, R. E., Onar-Thomas, A., Wu, S. et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2014a pediatric brain tumor consortium study. Neuro. Oncol. 16, 310\u2013317 (2014).","journal-title":"Neuro. Oncol."},{"key":"1107_CR144","doi-asserted-by":"crossref","first-page":"368","DOI":"10.15252\/emmm.201404271","volume":"7","author":"A McIntyre","year":"2015","unstructured":"McIntyre, A. & Harris, A. L. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7, 368\u2013379 (2015).","journal-title":"EMBO Mol. Med."},{"key":"1107_CR145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/14756366.2018.1532419","volume":"34","author":"E Andreucci","year":"2019","unstructured":"Andreucci, E., Ruzzolini, J., Peppicelli, S., Bianchini, F., Laurenzana, A., Carta, F. et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J. Enzym. Inhib. Med. Chem. 34, 117\u2013123 (2019).","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"1107_CR146","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","volume":"27","author":"CT Supuran","year":"2018","unstructured":"Supuran, C. T. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin. Investig. Drugs 27, 963\u2013970 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1107_CR147","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cmdc.201600276","volume":"11","author":"H Siebeneicher","year":"2016","unstructured":"Siebeneicher, H., Cleve, A., Rehwinkel, H., Neuhaus, R., Heisler, I., M\u00fcller, T. et al. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem 11, 2261\u20132271 (2016).","journal-title":"ChemMedChem"},{"key":"1107_CR148","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00280-016-3007-9","volume":"77","author":"F Zhao","year":"2016","unstructured":"Zhao, F., Ming, J., Zhou, Y. & Fan, L. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother. Pharmacol. 77, 963\u2013972 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1107_CR149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0187314","volume":"12","author":"S Sethumadhavan","year":"2017","unstructured":"Sethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A. et al. Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells. PLoS ONE 12, 1\u201318 (2017).","journal-title":"PLoS ONE"},{"key":"1107_CR150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum, I. B., Smallwood, C. A., Siemens, D. R. & Graham, C. H. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665\u2013674 (2014).","journal-title":"Cancer Res."},{"key":"1107_CR151","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1172\/JCI126044","volume":"129","author":"MW Dewhirst","year":"2019","unstructured":"Dewhirst, M. W., Mowery, Y. M., Mitchell, J. B., Cherukuri, M. K. & Secomb, T. W. Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies. J. Clin. Investig. 129, 489\u2013491 (2019).","journal-title":"J. Clin. Investig."},{"key":"1107_CR152","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","volume":"128","author":"P Jayaprakash","year":"2018","unstructured":"Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J. et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J. Clin. Investig. 128, 5137\u20135149 (2018).","journal-title":"J. Clin. Investig."},{"key":"1107_CR153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2019.05.021","volume":"458","author":"A Lequeux","year":"2019","unstructured":"Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E. et al. Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. Cancer Lett. 458, 13\u201320 (2019).","journal-title":"Cancer Lett."},{"key":"1107_CR154","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","volume":"7","author":"SC Chafe","year":"2019","unstructured":"Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S. et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol. Res. 7, 1064\u20131078 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1107_CR155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","volume":"31","author":"RG Majzner","year":"2017","unstructured":"Majzner, R. G., Heitzeneder, S. & Mackall, C. L. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell 31, 476\u2013485 (2017).","journal-title":"Cancer Cell"},{"key":"1107_CR156","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10555-019-09836-y","volume":"38","author":"P Kattner","year":"2019","unstructured":"Kattner, P., Strobel, H., Khoshnevis, N., Grunert, M., Bartholomae, S., Pruss, M. et al. Compare and contrast: pediatric cancer versus adult malignancies. Cancer Metastasis Rev. 38, 673\u2013682 (2019).","journal-title":"Cancer Metastasis Rev."},{"key":"1107_CR157","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","volume":"20","author":"MF Wedekind","year":"2018","unstructured":"Wedekind, M. F., Denton, N. L., Chen, C. Y. & Cripe, T. P. Pediatric cancer immunotherapy: opportunities and challenges. Pediatr. Drugs 20, 395\u2013408 (2018).","journal-title":"Pediatr. Drugs"},{"key":"1107_CR158","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","volume":"127","author":"JH Park","year":"2016","unstructured":"Park, J. H., Geyer, M. B. & Brentjens, R. J. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127, 3312\u20133320 (2016).","journal-title":"Blood"},{"key":"1107_CR159","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.08.005","volume":"15","author":"B Hutzen","year":"2019","unstructured":"Hutzen, B., Ghonime, M., Lee, J., Mardis, E. R., Wang, R., Lee, D. A. et al. Immunotherapeutic challenges for pediatric cancers. Mol. Ther. - Oncolytics 15, 38\u201348 (2019).","journal-title":"Mol. Ther. - Oncolytics"},{"key":"1107_CR160","doi-asserted-by":"crossref","first-page":"20180036","DOI":"10.1259\/bjr.20180945","volume":"92","author":"L Yang","year":"2019","unstructured":"Yang, L. & West, C. M. L. Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. Br. J. Radiol. 92, 20180036 (2019).","journal-title":"Br. J. Radiol."},{"key":"1107_CR161","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1667\/RR0888.1","volume":"169","author":"B Wen","year":"2008","unstructured":"Wen, B., Urano, M., Humm, J. L., Seshan, V. E., Li, G. C. & Ling, C. C. Comparison of Helzel and OxyLite systems in the measurements of tumor partial oxygen pressure (pO2). Radiat. Res. 169, 67\u201375 (2008).","journal-title":"Radiat. Res."},{"key":"1107_CR162","doi-asserted-by":"crossref","unstructured":"Hughes, V. S., Wiggins, J. M. & Siemann, D. W. Tumor oxygenation and cancer therapy\u2014then and now. Br. J. Radiol. 91, 20170955 (2018).","DOI":"10.1259\/bjr.20170955"},{"key":"1107_CR163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-11-167","volume":"11","author":"SE Rademakers","year":"2011","unstructured":"Rademakers, S. E., Lok, J., Van Der Kogel, A. J., Bussink, J. & Kaanders, J. H. A. M. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1a, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11, 1\u201310 (2011).","journal-title":"BMC Cancer"},{"key":"1107_CR164","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/bjc.2014.610","volume":"112","author":"IN Fleming","year":"2015","unstructured":"Fleming, I. N., Manavaki, R., Blower, P. J., West, C., Williams, K. J., Harris, A. L. et al. Imaging tumour hypoxia with positron emission tomography. Br. J. Cancer 112, 238\u2013250 (2015).","journal-title":"Br. J. Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01107-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T09:14:07Z","timestamp":1723799647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":164,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,2]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01107-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"C.B. is funded by Alice\u2019s Arc Children\u2019s Cancer Charity. Y.K.S.M. received support from the Little Princess Trust Research Grant (CCLGA 201720). J.C.C. receives support from the Royal Marsden Cancer Charity and is supported by National Health Service funding to the National Institute for Health Research Biomedical Research Centre of The Royal Marsden Hospital. E.Y.L. and S.P.R. acknowledge the support received from The Oracle Cancer Trust and Cancer Research UK (grant C16412\/A27725).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}